Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 90

1.

Signaling pathway models as biomarkers: Patient-specific simulations of JNK activity predict the survival of neuroblastoma patients.

Fey D, Halasz M, Dreidax D, Kennedy SP, Hastings JF, Rauch N, Munoz AG, Pilkington R, Fischer M, Westermann F, Kolch W, Kholodenko BN, Croucher DR.

Sci Signal. 2015 Dec 22;8(408):ra130. doi: 10.1126/scisignal.aab0990.

PMID:
26696630
2.

MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma.

Zhang S, Wei JS, Li SQ, Badgett TC, Song YK, Agarwal S, Coarfa C, Tolman C, Hurd L, Liao H, He J, Wen X, Liu Z, Thiele CJ, Westermann F, Asgharzadeh S, Seeger RC, Maris JM, Guidry Auvil JM, Smith MA, Kolaczyk ED, Shohet J, Khan J.

Cancer Lett. 2016 Feb 28;371(2):214-24. doi: 10.1016/j.canlet.2015.11.045. Epub 2015 Dec 10.

PMID:
26683771
3.

Integrative omics reveals MYCN as a global suppressor of cellular signalling and enables network-based therapeutic target discovery in neuroblastoma.

Duffy DJ, Krstic A, Halasz M, Schwarzl T, Fey D, Iljin K, Mehta JP, Killick K, Whilde J, Turriziani B, Haapa-Paananen S, Fey V, Fischer M, Westermann F, Henrich KO, Bannert S, Higgins DG, Kolch W.

Oncotarget. 2015 Dec 22;6(41):43182-201. doi: 10.18632/oncotarget.6568.

4.

Targeting MYCN-driven transcription by BET-bromodomain inhibition.

Henssen AG, Althoff K, Odersky A, Beckers A, Koche R, Speleman F, Schaefer S, Bell E, Nortmeyer M, Westermann F, De Preter K, Florin A, Heukamp L, Spruessel A, Astrahanseff K, Lindner S, Solomentsew N, Schramm A, Astorgues-Xerri L, Riveiro ME, Eggert A, Cvitkovic E, Schulte JH.

Clin Cancer Res. 2015 Dec 2. pii: clincanres.1449.2015. [Epub ahead of print]

PMID:
26631615
5.

Transcription factor activating protein 2 beta (TFAP2B) mediates noradrenergic neuronal differentiation in neuroblastoma.

Ikram F, Ackermann S, Kahlert Y, Volland R, Roels F, Engesser A, Hertwig F, Kocak H, Hero B, Dreidax D, Henrich KO, Berthold F, Nürnberg P, Westermann F, Fischer M.

Mol Oncol. 2016 Feb;10(2):344-59. doi: 10.1016/j.molonc.2015.10.020. Epub 2015 Nov 7.

PMID:
26598443
6.

Telomerase activation by genomic rearrangements in high-risk neuroblastoma.

Peifer M, Hertwig F, Roels F, Dreidax D, Gartlgruber M, Menon R, Krämer A, Roncaioli JL, Sand F, Heuckmann JM, Ikram F, Schmidt R, Ackermann S, Engesser A, Kahlert Y, Vogel W, Altmüller J, Nürnberg P, Thierry-Mieg J, Thierry-Mieg D, Mariappan A, Heynck S, Mariotti E, Henrich KO, Gloeckner C, Bosco G, Leuschner I, Schweiger MR, Savelyeva L, Watkins SC, Shao C, Bell E, Höfer T, Achter V, Lang U, Theissen J, Volland R, Saadati M, Eggert A, de Wilde B, Berthold F, Peng Z, Zhao C, Shi L, Ortmann M, Büttner R, Perner S, Hero B, Schramm A, Schulte JH, Herrmann C, O'Sullivan RJ, Westermann F, Thomas RK, Fischer M.

Nature. 2015 Oct 29;526(7575):700-4. doi: 10.1038/nature14980. Epub 2015 Oct 14.

PMID:
26466568
7.

Toxicity and utilization of chemical weapons: does toxicity and venom utilization contribute to the formation of species communities?

Westermann FL, McPherson IS, Jones TH, Milicich L, Lester PJ.

Ecol Evol. 2015 Aug;5(15):3103-13. doi: 10.1002/ece3.1595. Epub 2015 Jul 14.

8.

MYCN-driven regulatory mechanisms controlling LIN28B in neuroblastoma.

Beckers A, Van Peer G, Carter DR, Gartlgruber M, Herrmann C, Agarwal S, Helsmoortel HH, Althoff K, Molenaar JJ, Cheung BB, Schulte JH, Benoit Y, Shohet JM, Westermann F, Marshall GM, Vandesompele J, De Preter K, Speleman F.

Cancer Lett. 2015 Sep 28;366(1):123-32. doi: 10.1016/j.canlet.2015.06.015. Epub 2015 Jun 26.

PMID:
26123663
9.

Mutational dynamics between primary and relapse neuroblastomas.

Schramm A, Köster J, Assenov Y, Althoff K, Peifer M, Mahlow E, Odersky A, Beisser D, Ernst C, Henssen AG, Stephan H, Schröder C, Heukamp L, Engesser A, Kahlert Y, Theissen J, Hero B, Roels F, Altmüller J, Nürnberg P, Astrahantseff K, Gloeckner C, De Preter K, Plass C, Lee S, Lode HN, Henrich KO, Gartlgruber M, Speleman F, Schmezer P, Westermann F, Rahmann S, Fischer M, Eggert A, Schulte JH.

Nat Genet. 2015 Aug;47(8):872-7. doi: 10.1038/ng.3349. Epub 2015 Jun 29.

PMID:
26121086
10.

Synthetic pheromones as a management technique - dispensers reduce Linepithema humile activity in a commercial vineyard.

Westermann FL, Bell VA, Suckling DM, Lester PJ.

Pest Manag Sci. 2015 May 21. doi: 10.1002/ps.4043. [Epub ahead of print]

PMID:
25997391
11.

Identification of flubendazole as potential anti-neuroblastoma compound in a large cell line screen.

Michaelis M, Agha B, Rothweiler F, Löschmann N, Voges Y, Mittelbronn M, Starzetz T, Harter PN, Abhari BA, Fulda S, Westermann F, Riecken K, Spek S, Langer K, Wiese M, Dirks WG, Zehner R, Cinatl J, Wass MN, Cinatl J Jr.

Sci Rep. 2015 Feb 3;5:8202. doi: 10.1038/srep08202.

12.

Large-scale tracking and classification for automatic analysis of cell migration and proliferation, and experimental optimization of high-throughput screens of neuroblastoma cells.

Harder N, Batra R, Diessl N, Gogolin S, Eils R, Westermann F, König R, Rohr K.

Cytometry A. 2015 Jun;87(6):524-40. doi: 10.1002/cyto.a.22632. Epub 2015 Jan 28.

PMID:
25630981
13.

Revised risk estimation and treatment stratification of low- and intermediate-risk neuroblastoma patients by integrating clinical and molecular prognostic markers.

Oberthuer A, Juraeva D, Hero B, Volland R, Sterz C, Schmidt R, Faldum A, Kahlert Y, Engesser A, Asgharzadeh S, Seeger R, Ohira M, Nakagawara A, Scaruffi P, Tonini GP, Janoueix-Lerosey I, Delattre O, Schleiermacher G, Vandesompele J, Speleman F, Noguera R, Piqueras M, Bénard J, Valent A, Avigad S, Yaniv I, Grundy RG, Ortmann M, Shao C, Schwab M, Eils R, Simon T, Theissen J, Berthold F, Westermann F, Brors B, Fischer M.

Clin Cancer Res. 2015 Apr 15;21(8):1904-15. doi: 10.1158/1078-0432.CCR-14-0817. Epub 2014 Sep 17.

PMID:
25231397
14.

A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies.

Althoff K, Beckers A, Bell E, Nortmeyer M, Thor T, Sprüssel A, Lindner S, De Preter K, Florin A, Heukamp LC, Klein-Hitpass L, Astrahantseff K, Kumps C, Speleman F, Eggert A, Westermann F, Schramm A, Schulte JH.

Oncogene. 2015 Jun;34(26):3357-68. doi: 10.1038/onc.2014.269. Epub 2014 Sep 1.

15.

p19-INK4d inhibits neuroblastoma cell growth, induces differentiation and is hypermethylated and downregulated in MYCN-amplified neuroblastomas.

Dreidax D, Bannert S, Henrich KO, Schröder C, Bender S, Oakes CC, Lindner S, Schulte JH, Duffy D, Schwarzl T, Saadati M, Ehemann V, Benner A, Pfister S, Fischer M, Westermann F.

Hum Mol Genet. 2014 Dec 20;23(25):6826-37. doi: 10.1093/hmg/ddu406. Epub 2014 Aug 7.

16.

NOTCH ligands JAG1 and JAG2 as critical pro-survival factors in childhood medulloblastoma.

Fiaschetti G, Schroeder C, Castelletti D, Arcaro A, Westermann F, Baumgartner M, Shalaby T, Grotzer MA.

Acta Neuropathol Commun. 2014 Apr 7;2:39. doi: 10.1186/2051-5960-2-39.

17.

Disruption of foraging by a dominant invasive species to decrease its competitive ability.

Westermann FL, Suckling DM, Lester PJ.

PLoS One. 2014 Mar 4;9(3):e90173. doi: 10.1371/journal.pone.0090173. eCollection 2014.

18.

Testing of SNS-032 in a Panel of Human Neuroblastoma Cell Lines with Acquired Resistance to a Broad Range of Drugs.

Löschmann N, Michaelis M, Rothweiler F, Zehner R, Cinatl J, Voges Y, Sharifi M, Riecken K, Meyer J, von Deimling A, Fichtner I, Ghafourian T, Westermann F, Cinatl J Jr.

Transl Oncol. 2013 Dec 1;6(6):685-96. eCollection 2013 Dec 1.

19.

GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3.

Fabian J, Lodrini M, Oehme I, Schier MC, Thole TM, Hielscher T, Kopp-Schneider A, Opitz L, Capper D, von Deimling A, Wiegand I, Milde T, Mahlknecht U, Westermann F, Popanda O, Roels F, Hero B, Berthold F, Fischer M, Kulozik AE, Witt O, Deubzer HE.

Cancer Res. 2014 May 1;74(9):2604-16. doi: 10.1158/0008-5472.CAN-13-1904. Epub 2014 Jan 13.

20.

Cell survival signalling through PPARδ and arachidonic acid metabolites in neuroblastoma.

Bell E, Ponthan F, Whitworth C, Westermann F, Thomas H, Redfern CP.

PLoS One. 2013 Jul 9;8(7):e68859. doi: 10.1371/journal.pone.0068859. Print 2013.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk